Welcome to our dedicated page for Adicet Bio news (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Adicet Bio Inc (ACET) is a clinical-stage biotechnology company pioneering allogeneic gamma delta T cell therapies for cancer treatment. This page serves as the definitive source for verified corporate developments, research milestones, and strategic updates.
Investors and industry observers will find timely updates on clinical trial progress, regulatory milestones, and partnership announcements. Our curated collection includes press releases covering therapy pipeline advancements, financial disclosures, and scientific collaborations, with particular focus on the company's CAR/TCR engineering platform and TCR-like antibody research.
Key content categories include updates on lead candidate ADI-001 for B-cell malignancies, preclinical developments for solid tumor targets like CD70, and strategic initiatives such as the Regeneron Pharmaceuticals collaboration. All materials are vetted for accuracy and relevance to investment analysis.
Bookmark this page for streamlined access to essential updates about Adicet Bio's innovative approach to universal cell therapies. Check regularly for new developments in their mission to advance off-the-shelf immunotherapies for oncology applications.
Adicet Bio, Inc. (Nasdaq: ACET) announced that its lead candidate, ADI-001, will be presented at the 63rd American Society of Hematology Annual Meeting on December 12, 2021. The presentation will detail the Phase 1 study aimed at evaluating the safety and tolerability of ADI-001, targeted at treating B Cell Malignancies. Interim clinical data is expected by the end of 2021. The abstract will also be published in Blood's November supplemental issue. Adicet is focused on developing allogeneic gamma delta T cell therapies for cancer.
Adicet Bio, Inc. (Nasdaq: ACET) has announced the promotion of Blake Aftab, Ph.D., to Senior Vice President and Chief Scientific Officer. Dr. Aftab's new role focuses on expanding Adicet’s pipeline for cancer therapies, particularly in solid and hematologic tumors. His leadership is expected to enhance ongoing research, including the Phase 1 trial of ADI-001 for non-Hodgkin’s lymphoma. The company anticipates revealing interim data for ADI-001 later this year, marking a significant development in gamma delta CAR-T cell therapy.
Adicet Bio, Inc. (Nasdaq: ACET) announced a poster presentation for its allogeneic gamma delta CAR T cell therapy, ADI-002, at the Society for Immunotherapy of Cancer's 36th Annual Meeting, scheduled for November 10-14, 2021. The poster, titled "ADI-002: an IL-15 armored allogeneic 'off-the-shelf' Vδ1 gamma delta CAR T cell therapy for solid tumors targeting glypican-3 (GPC3)," will be presented from November 12-14, 2021. This development emphasizes Adicet's focus on innovative cancer therapies and marks a significant step in its clinical strategy.
Twist Bioscience (NASDAQ: TWST) and Adicet Bio (NASDA: ACET) have announced a collaboration aimed at accelerating the discovery of gamma delta T cell therapies targeting five undisclosed cancer-related antigens. Twist will utilize its proprietary antibody discovery technologies to aid in engineering immune cells with novel chimeric antigen receptors (CARs), enhancing Adicet's pipeline. The agreement includes an upfront technology licensing fee, clinical and regulatory milestones, and product royalties, emphasizing the partnership's potential in advancing T cell therapies for cancer treatment.
Adicet Bio (Nasdaq: ACET) has partnered with Twist Bioscience to enhance the development of gamma delta T cell therapies targeting five undisclosed cancer markers. This collaboration aims to utilize Twist’s advanced antibody discovery technologies to engineer immune cells equipped with human CARs and TCRs, potentially improving tumor cell recognition and eradication. Twist will receive an upfront technology license fee, alongside milestone payments and royalties from successful products arising from the partnership. Both companies express optimism about accelerating treatment options for cancer patients.
Adicet Bio, Inc. (Nasdaq: ACET) announced its participation in two virtual investor conferences in September 2021. The first is the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, where attendees can access a recorded presentation starting September 13 at 7:00 AM ET. The second event is the 2021 Cantor Virtual Global Healthcare Conference, featuring a fireside chat by CEO Chen Schor on September 27 at 10:00 AM ET. Live and archived audio webcasts will be available on Adicet Bio’s investor website.
Adicet Bio (Nasdaq: ACET) announced its Q2 2021 results, highlighting operational achievements and progress in its lead asset, ADI-001, for Non-Hodgkin's Lymphoma. The company expects to report interim data by 2021's end and has added a scientific advisory board to support its pipeline. Financially, R&D expenses rose to $10.6M, while G&A expenses decreased to $5.0M. The net loss was $10.9M, with a cash position of $208.7M expected to fund operations into mid-2023. Adicet's addition to the Russell 2000 Index could enhance investor visibility.
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology firm focused on allogeneic gamma delta T cell therapies, announced participation in three virtual investor conferences in August 2021. Key highlights include a fireside chat by CEO Chen Schor at the BTIG Virtual Biotechnology Conference on August 9 at 9:00 AM ET and a panel discussion on August 10 during the Wedbush PacGrow Healthcare Conference, as well as another fireside chat on August 11 at the Canaccord Genuity Annual Growth Conference. A webcast will be available on their investor website.
Adicet Bio (Nasdaq: ACET) announced the formation of a Scientific Advisory Board (SAB) on July 15, 2021. This board comprises distinguished experts in T cell biology, immunology, and oncology, who will provide strategic guidance for advancing Adicet’s lead asset, ADI-001, and its gamma delta T cell therapies. Key members include renowned doctors such as Alice Bertaina, Marco Davila, and Michael Kalos. The new board is expected to enhance the development of innovative cancer treatments, boosting Adicet's potential in the biotechnology sector.
Adicet Bio, Inc. (Nasdaq: ACET) announced its addition to the Russell 2000 Index, effective June 28, 2021. This inclusion reflects the significant progress the company has made in developing allogeneic gamma delta T cell therapies for cancer treatment. CEO Chen Schor expressed optimism that this recognition will enhance visibility for its gamma delta T cell product pipeline. Adicet is expected to release interim clinical data from its lead candidate ADI-001 later this year. The Russell Indexes are utilized widely by institutional investors, managing approximately $10.6 trillion in assets.
FAQ
What is the current stock price of Adicet Bio (ACET)?
What is the market cap of Adicet Bio (ACET)?
